Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00726687 | Phase 1b Study of Indibulin in Combination With Capecitabine in Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 7 | Alaunos TherapeuticsINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05103358 | Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) | completed | Phase 2 | 128 | Aadi Bioscience, Inc.INDUSTRY | 3 | Sep 28, 2026 | clinicaltrials |
| NCT03568656 | Study to Evaluate CCS1477 in Advanced Tumours | completed | Phase 1 / Phase 2 | 219 | CellCentric Ltd.INDUSTRY | 6 | Sep 25, 2026 | clinicaltrials |
| NCT04083976 | A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations(RAGNAR) | completed | Phase 2 | 316 | Janssen Research & Development, LLCINDUSTRY | 15 | Sep 17, 2026 | clinicaltrials |
| NCT04896697 | Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 125 | Xilio Development, Inc.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT05864144 | A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 98 | Sensei Biotherapeutics, Inc.INDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04902872 | Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 69 | Cybrexa TherapeuticsINDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT00918320 | Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Paediatric Solid Tumours(TOTEM2) | completed | Phase 2 | 129 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06059547 | Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer | completed | Phase 2 | 31 | CatalYm GmbHINDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05407675 | A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 68 | Bristol-Myers SquibbINDUSTRY | 5 | Aug 13, 2026 | clinicaltrials |
| NCT06139211 | A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 66 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT04386967 | OH2 Injection in Solid Tumors | completed | Phase 1 / Phase 2 | 44 | Binhui Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT04905914 | Study Of ATRN-119 In Patients With Advanced Solid Tumors(ABOYA-119) | completed | Phase 1 / Phase 2 | 43 | Aprea TherapeuticsINDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT06076135 | Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Solid Tumors(ILDR-01) | completed | Phase 2 | 24 | Chuangzhen ChenOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT06614140 | Personalized Neoantigen Cancer Vaccine for Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 8 | Seqker Biosciences, Inc.INDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT04826341 | A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors | completed | Phase 1 / Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jul 21, 2026 | clinicaltrials |
| NCT05512377 | Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder | completed | Phase 2 | 99 | Boehringer IngelheimINDUSTRY | 16 | Jul 21, 2026 | clinicaltrials |
| NCT06470763 | A Study Evaluating ANV600 Single Agent or in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (EXPAND-1) | completed | Phase 1 / Phase 2 | 63 | Anaveon AGINDUSTRY | 7 | Jul 10, 2026 | clinicaltrials |
| NCT02710253 | Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy | completed | Phase 2 | 214 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT05991349 | A Study of IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 36 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 2 | Jun 24, 2026 | clinicaltrials |
| NCT05708950 | A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) | completed | Phase 1 / Phase 2 | 40 | Kineta Inc.INDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT06242691 | Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors (MK-1200-002) | completed | Phase 1 / Phase 2 | 13 | Merck Sharp & Dohme LLCINDUSTRY | 6 | Jun 5, 2026 | clinicaltrials |
| NCT04552288 | Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies | completed | Phase 2 | 51 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05052268 | XTX202 in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 95 | Xilio Development, Inc.INDUSTRY | 1 | May 28, 2026 | clinicaltrials |
| NCT02444741 | Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 124 | M.D. Anderson Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT05173142 | A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 190 | Hutchison Medipharma LimitedINDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT03735095 | Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer | completed | Phase 1 / Phase 2 | 19 | Roswell Park Cancer InstituteOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT04322006 | A Phase I/II Study of TJ004309 for Advanced Solid Tumor | completed | Phase 1 / Phase 2 | 225 | TJ Biopharma Co., Ltd.INDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT03797326 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) | completed | Phase 2 | 611 | Merck Sharp & Dohme LLCINDUSTRY | 17 | May 4, 2026 | clinicaltrials |
| NCT05865990 | HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease(TUXEDO-3) | completed | Phase 2 | 63 | MedSIROTHER | 2 | May 4, 2026 | clinicaltrials |
| NCT04118114 | Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors | completed | Phase 2 | 14 | National Cancer Centre, SingaporeOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT01625234 | Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 131 | Xcovery Holdings, Inc.INDUSTRY | 1 | Apr 30, 2026 | clinicaltrials |
| NCT02661542 | Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas | completed | Phase 1 / Phase 2 | 106 | Fujifilm Pharmaceuticals U.S.A., Inc.INDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT03213678 | Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 2 | Apr 21, 2026 | clinicaltrials |
| NCT04174716 | Basket Trial of IDX-1197, a PARP Inhibitor, in Patients With HRR Mutated Solid Tumors (VASTUS)(VASTUS) | completed | Phase 1 / Phase 2 | 108 | Idience Co., Ltd.INDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT04886271 | Recombinant Humanized Anti-CD47 / PD-1 Bifunctional Antibody HX009 Injection in the Treatment of Advanced Solid Tumors | completed | Phase 2 | 20 | Hangzhou Hanx Biopharmaceuticals, Ltd.INDUSTRY | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03213665 | Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 2 | Apr 13, 2026 | clinicaltrials |
| NCT04420884 | A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors(iintune-1) | completed | Phase 1 / Phase 2 | 248 | TakedaINDUSTRY | 11 | Apr 8, 2026 | clinicaltrials |
| NCT04983901 | PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN | completed | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT03526250 | Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 2 | Apr 3, 2026 | clinicaltrials |
| NCT04911907 | Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Solid Tumors | completed | Phase 2 | 126 | Beijing Biostar Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT06036836 | Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) | completed | Phase 2 | 163 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Mar 19, 2026 | clinicaltrials |
| NCT04143711 | Study of DF1001 in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 270 | Dragonfly TherapeuticsINDUSTRY | 6 | Mar 18, 2026 | clinicaltrials |
| NCT04705818 | Combining Epigenetic And Immune Therapy to Beat Cancer.(CAIRE) | completed | Phase 2 | 164 | Institut BergoniéOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT04238819 | A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma | completed | Phase 1 / Phase 2 | 47 | Eli Lilly and CompanyINDUSTRY | 8 | Mar 2, 2026 | clinicaltrials |
| NCT04233567 | Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations | completed | Phase 2 | 17 | Sameek RoychowdhuryOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT04282018 | Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab | completed | Phase 1 / Phase 2 | 97 | BeiGeneINDUSTRY | 2 | Feb 20, 2026 | clinicaltrials |
| NCT05419375 | Screening Study for Participants With Malignant Tumors | completed | Phase 2 | 470 | Hoffmann-La RocheINDUSTRY | 26 | Feb 3, 2026 | clinicaltrials |
| NCT03697304 | Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours | completed | Phase 2 | 211 | Boehringer IngelheimINDUSTRY | 3 | Jan 27, 2026 | clinicaltrials |
Data updated 5 hours agoSource updated Sep 29, 2026source: clinicaltrials